Roche Ups Outlook, Sees Spark Buy By Year-End
New Medicines Help Group Lift Full-Year Guidance (Again)
Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.
You may also be interested in...
US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay the launch of a gene therapy for hemophilia A.
Capitol Forum reports that FTC staff have recommended the proposed acquisition of Spark by Roche be approved without requiring any asset sales. The end could be in sight for the long-drawn out affair.
Roche's main consideration when partnering is to "access great science" regardless of location. More of this is expected to come out of Asia, its global partnering head tells Scrip.